The iDiabetes Platform: Enhanced Phenotyping of Patients with Diabetes for Precision Diagnosis, Prognosis and Treatment - study protocol for a cluster-randomised controlled study in Tayside, Scotland
Authors:
Preprint
Abstract
Introduction and Aim: Diabetes is a global health emergency with increasing prevalence and diabetes-associated morbidity and mortality. One of the challenges in optimising diabetes care is translating research advances in this heterogenous disease into clinical care. A potential solution is the introduction of precision medicine approaches into diabetes care. We aim to develop a digital platform called ‘intelligent Diabetes’ (iDiabetes) to support a precision diabetes care model in Scotland and assess its impact on the primary composite outcome of all-cause mortality, hospitalisation rate, renal function decline and glycaemic control. Methods and Analysis: The impact of iDiabetes will be evaluated through a cluster-randomised controlled study, recruiting up to 22,500 patients with diabetes. Primary care general practices (GP) in the National Health Service Scotland Tayside Health Board are the units (clusters) of randomisation. Each primary care GP will form one cluster (approximately 400 patients per cluster), with up to 60 clusters recruited. Randomisation will be to iDiabetes (guideline support) , iDiabetesPlus or usual diabetes care (control arm). Patients of participating primary care GPs are automatically enrolled to the study when they attend for their annual diabetes screening or are newly diagnosed with diabetes. A composite hierarchical primary outcome, evaluated using Win-Ratio statistical methodology, will consists of (I) all-cause mortality, (II) all-cause hospitalisation rate, (III) proportion with >40% eGFR reduction from baseline or new development of end-stage renal disease, (IV) proportion with absolute HbA1C reduction >0.5%. Outcomes will be evaluated after a 2-year median follow-up period. Comprehensive qualitative and health economic analyses will be conducted, assessing the cost-effectiveness, budget impact and user acceptability of the iDiabetes platform. Ethics and Dissemination: This study was reviewed by the NHS HRA and approved by East of Scotland Research Ethics Committee (reference:23/ES/0008). Study findings will be disseminated via publications, presented at scientific conferences and shared with patients and the public on the study website and social media. Study registration ISRCTN18000901 Study Sponsor University of Dundee, no. 2-026-22. Contact: tascgovernance@dundee.ac.uk Protocol version: V3.0, 22/09/2023 ARTICLE SUMMARY: Strengths iDiabetes is a novel precision medicine platform which is the first of its kind to evaluate a precision diabetes care model in a controlled trial Real-world application in an existing healthcare system, with the entire regional diabetes population eligible for enrolment – results are therefore likely to be generalisable and the approach could be scaled up to a national level The study analysis utilises a mixed-method approach allowing a comprehensive evaluation of all aspects of the precision medicine platform including impact on clinical outcomes, usability for both patients and clinicians, cost-effectiveness analysis, budget impact analysis and patient preferences. Limitations: Study enrolment takes place when patients attend their routine clinical diabetes review - consequently a subpopulation of patients with limited healthcare access may be excluded The patient-facing platform is only available in an English version and can only be accessed digitally, therefore patients with limited English or digital illiteracy may not benefit from the intervention to its full potentialKeywords
All Related Versions
- Published version: BMJ Open, 14 (11), e086594.
This publication has 21 references indexed in Scilit:
- Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021The Lancet, 2023
- Heterogeneity in phenotype, disease progression and drug response in type 2 diabetesNature Medicine, 2022
- Inference on win ratio for cluster-randomized semi-competing risk dataJapanese Journal of Statistics and Data Science, 2021
- The win ratio approach for composite endpoints: practical guidance based on previous experienceEuropean Heart Journal, 2020
- Painting a new picture of personalised medicine for diabetesDiabetologia, 2017
- Assessing the cost‐effectiveness of Type 1 diabetes interventions: the Sheffield Type 1 Diabetes Policy ModelDiabetic Medicine, 2014
- Sample size requirements for stated choice experimentsTransportation, 2013
- What is an adequate sample size? Operationalising data saturation for theory-based interview studiesPsychology & Health, 2010
- Switching from Insulin to Oral Sulfonylureas in Patients with Diabetes Due to Kir6.2 MutationsNew England Journal of Medicine, 2006
- Genetic cause of hyperglycaemia and response to treatment in diabetesThe Lancet, 2003